Our pipeline

Programs designed to combat antimicrobial resistance and cancer

Our product pipeline comprises three programs, a vaccine for the treatment and prevention of recurrent UTIs, and programs that target cancers and bacterial infections.

View our pipeline

SEQ-400 for recurrent UTIs

Our leading program, SEQ-400, is a FimH vaccine that is being investigated for the prevention of recurrent urinary tract infections.

SEQ-1274 Drug Platform for ovarian/uterine cancer

Our oncology drug candidates derive from a small-molecule platform focused on the treatment of ovarian and other cancers.

Novel Small Molecule Drug Platform for cystic fibrosis

Our third program is optimizing novel lead compounds for the treatment of lung infections in cystic fibrosis patients.

Scientific leaders putting patients first

We have an exceptional leadership team that brings together over 100 years of combined experience in pharmaceutical R&D, clinical development, and manufacturing, as well as a highly reputable scientific advisory board that includes key opinion leaders on recurrent UTIs.